Gilead Sciences has partnered with digital health company Manta Cares to get tools for navigating lung and breast cancer care pathways to patients.
Manta launched a planner in 2021 to help cancer patients track treatment options, monitor symptoms and otherwise stay on top of the admin associated with oncology care. Having originally created a paper planner for all cancers, Manta went on to set up a digital platform and tailor its tools to different tumor types. The company said last year that it works with three of the top 15 drugmakers.
Gilead’s involvement will support the nationwide distribution of customized navigation tools for lung and breast cancers, two tumor types targeted by the pharma’s antibody-drug conjugate Trodelvy. The ADC, which generated (PDF) sales of $1.4 billion last year, is approved in two types of breast cancer and in development in lung cancer.
The drugmaker will specifically help roll out across the U.S. Manta’s customized planner for metastatic non-small cell lung cancer, which the digital health company developed with input from the nonprofit LUNGevity Foundation.
The collaboration will also encompass real-world pilot programs, community outreach and ongoing research, according to the companies’ joint announcement.
Elsewhere, as part of the team-up, Gilead is lending its support to ongoing studies by independent investigators into how patients and providers use the Manta platform in real-world settings. So far, the research has found that patients use the planners to organize questions, track medications and appointments, and structure their conversations with care teams, all of which helps them feel “more confident and prepared,” per the release.
Gilead has played a role in some previous assessments of Manta’s tools. The pharma was involved in recruiting patients in a study of Manta’s cancer care web app that began in 2024, and it also provided funding for a study of the company’s digital navigation platform that reported results last year.
The latest news of Gilead’s work with Manta arrives at an important moment for the drugmaker’s cancer plans. Gilead has said (PDF) that it expects the FDA to rule on filings for approval of Trodelvy in two more types of breast cancer in the second half of the year, and the company plans to provide updates on phase 3 trials of the ADC in non-small cell lung cancer and endometrial cancer over the same time frame.